Veradigm Introduces Cardiometabolic Clinical Registry Datasets to Enhance the Next Generation of Real-World Research
Veradigm (OTCMKTS: MDRX) has launched seven new disease-specific cardiometabolic Clinical Data Registry datasets to enhance real-world research capabilities. The registries harmonize data from over 80 different electronic health records (EHRs), combining both structured and unstructured data to provide comprehensive insights into disease patterns and treatment outcomes.
The new registry cohorts include specialized datasets for Heart Failure, Atrial Fibrillation, ASCVD, Hypertension, Type 1 Diabetes, Type 2 Diabetes, and Chronic Kidney Disease. The company utilizes Natural Language Processing (NLP) to extract insights from clinical data, particularly focusing on details relevant to life science researchers, public health, and government regulators.
Veradigm (OTCMKTS: MDRX) ha lanciato sette nuovi dataset di registri clinici cardiometabolici specifici per malattie per migliorare le capacità di ricerca nel mondo reale. I registri armonizzano i dati provenienti da oltre 80 diversi registri elettronici di salute (EHR), combinando dati strutturati e non strutturati per fornire approfondimenti completi sui modelli di malattia e sugli esiti dei trattamenti.
Le nuove coorti di registri includono dataset specializzati per Insufficienza Cardiaca, Fibrillazione Atriale, ASCVD, Ipertensione, Diabete di Tipo 1, Diabete di Tipo 2 e Malattia Renale Cronica. L'azienda utilizza l'Elaborazione del Linguaggio Naturale (NLP) per estrarre informazioni dai dati clinici, concentrandosi in particolare su dettagli rilevanti per i ricercatori nel campo delle scienze della vita, la salute pubblica e i regolatori governativi.
Veradigm (OTCMKTS: MDRX) ha lanzado siete nuevos conjuntos de datos de registros clínicos cardiometabólicos específicos para enfermedades para mejorar las capacidades de investigación en el mundo real. Los registros armonizan datos de más de 80 registros electrónicos de salud (EHR), combinando datos tanto estructurados como no estructurados para proporcionar información integral sobre los patrones de enfermedades y los resultados de los tratamientos.
Las nuevas cohortes de registro incluyen conjuntos de datos especializados para Insuficiencia Cardíaca, Fibrilación Auricular, ASCVD, Hipertensión, Diabetes Tipo 1, Diabetes Tipo 2 y Enfermedad Renal Crónica. La empresa utiliza Procesamiento de Lenguaje Natural (NLP) para extraer información de los datos clínicos, enfocándose particularmente en detalles relevantes para los investigadores en ciencias de la vida, la salud pública y los reguladores gubernamentales.
Veradigm (OTCMKTS: MDRX)는 실제 연구 능력을 향상시키기 위해 질병별 심혈관 대사 임상 데이터 레지스트리 데이터 세트 7개를 출시했습니다. 이 레지스트리는 80개 이상의 전자 건강 기록(EHR)에서 데이터를 조화롭게 통합하여 구조화된 데이터와 비구조화된 데이터를 결합하여 질병 패턴과 치료 결과에 대한 포괄적인 통찰력을 제공합니다.
새로운 레지스트리 집단은 심부전, 심방세동, ASCVD, 고혈압, 제1형 당뇨병, 제2형 당뇨병 및 만성 신장 질환에 대한 전문화된 데이터 세트를 포함합니다. 이 회사는 자연어 처리(NLP)를 활용하여 임상 데이터에서 통찰력을 추출하며, 특히 생명 과학 연구자, 공공 건강 및 정부 규제 기관과 관련된 세부 사항에 초점을 맞추고 있습니다.
Veradigm (OTCMKTS: MDRX) a lancé sept nouveaux ensembles de données de registre clinique cardiométabolique spécifiques à des maladies pour améliorer les capacités de recherche en conditions réelles. Les registres harmonisent les données provenant de plus de 80 dossiers de santé électroniques (DSE), combinant des données structurées et non structurées pour fournir des informations complètes sur les modèles de maladies et les résultats des traitements.
Les nouvelles cohortes de registre incluent des ensembles de données spécialisés pour Insuffisance Cardiaque, Fibrillation Auriculaire, ASCVD, Hypertension, Diabète de Type 1, Diabète de Type 2 et Maladie Rénale Chronique. L'entreprise utilise le Traitement du Langage Naturel (NLP) pour extraire des informations des données cliniques, en se concentrant particulièrement sur des détails pertinents pour les chercheurs en sciences de la vie, la santé publique et les régulateurs gouvernementaux.
Veradigm (OTCMKTS: MDRX) hat sieben neue krankheitsspezifische kardiometabolische klinische Datenregister-Datensätze gestartet, um die Forschungsfähigkeiten in der realen Welt zu verbessern. Die Register harmonisieren Daten aus über 80 verschiedenen elektronischen Gesundheitsakten (EHRs) und kombinieren strukturierte sowie unstrukturierte Daten, um umfassende Einblicke in Krankheitsmuster und Behandlungsergebnisse zu bieten.
Die neuen Registerkohorten umfassen spezialisierte Datensätze für Herzinsuffizienz, Vorhofflimmern, ASCVD, Bluthochdruck, Typ-1-Diabetes, Typ-2-Diabetes und chronische Nierenerkrankung. Das Unternehmen nutzt die Verarbeitung natürlicher Sprache (NLP), um Erkenntnisse aus klinischen Daten zu gewinnen, wobei der Schwerpunkt auf relevanten Details für Lebenswissenschaftler, öffentliche Gesundheit und staatliche Regulierungsbehörden liegt.
- Launch of seven new specialized clinical data registry datasets
- Integration of data from 80+ different EHR systems
- Enhanced research capabilities through NLP technology
- None.
With the introduction of seven new disease-specific registry datasets, Veradigm is enabling deep, targeted research to drive innovation and enhance real-world clinical insights
Veradigm’s Clinical Data Registries harmonize data from over 80 different electronic health records (EHRs) into a research ready data model, leveraging both structured and unstructured data to provide precise insights into disease patterns, treatment outcomes, and patient care.
Veradigm’s new cardiometabolic disease registry cohorts include:
- Heart Failure Registry
- Atrial Fibrillation Registry
- ASCVD Registry
- Hypertension Registry
- Type 1 Diabetes Registry
- Type 2 Diabetes Registry
- Chronic Kidney Disease Registry
“Globally, cardiovascular disease and metabolic disorders are the number one leading cause of death,” said Stuart Green, Senior Vice President & General Manager of Life Sciences Business at Veradigm. “We’ve leveraged NLP to extract insights from unstructured and semi-structured clinical data to generate evidence, particularly looking for clinical details that are important for life science researchers, public health and government regulators.”
About Veradigm®
Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube.
© 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218122163/en/
Investors:
Jenny Gelinas
312-506-1237
jenny.gelinas@veradigm.com
Media:
Concetta Rasiarmos
630-740-3152
concetta.rasiarmos@veradigm.com
Source: Veradigm
FAQ
What are the 7 new registry datasets launched by Veradigm (MDRX)?
How many EHR systems does Veradigm's (MDRX) new registry platform integrate?
What technology does Veradigm (MDRX) use to analyze clinical data in its new registries?
What is the primary purpose of Veradigm's (MDRX) new cardiometabolic registry datasets?
